EA-2353 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
90網膜色素変性症1

90. 網膜色素変性症


臨床試験数 : 147 薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05392751
(ClinicalTrials.gov)
June 2, 202223/5/2022Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis PigmentosaOpen-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis PigmentosaRetinitis Pigmentosa;Retinitis Pigmentosa SyndromeDrug: EA-2353Endogena Therapeutics, IncNULLRecruiting18 YearsN/AAll14Phase 1/Phase 2United States